Rathod S, Agrawal Y, Nakhate K, Meeran M, Ojha S, Goyal S
Biomedicines. 2023; 11(10).
PMID: 37893016
PMC: 10604915.
DOI: 10.3390/biomedicines11102642.
Zhang Z, Yu Z, Yuan Y, Yang J, Wang S, Ma H
Mol Neurobiol. 2023; 60(9):5067-5089.
PMID: 37247071
DOI: 10.1007/s12035-023-03388-7.
Chou S, Ranganath T, Fish K, Lewis D, Sweet R
Sci Rep. 2022; 12(1):9605.
PMID: 35688916
PMC: 9187707.
DOI: 10.1038/s41598-022-13724-x.
Behl T, Makkar R, Sehgal A, Singh S, Makeen H, Albratty M
Int J Mol Sci. 2022; 23(10).
PMID: 35628545
PMC: 9147046.
DOI: 10.3390/ijms23105734.
Paudel P, Ross S, Li X
Curr Med Chem. 2021; 29(11):1827-1850.
PMID: 34165403
PMC: 9007087.
DOI: 10.2174/0929867328666210623144658.
Expression of the type 1 cannabinoid receptor (CB1R) in CCK-immunoreactive axon terminals in the basolateral amygdala of the rhesus monkey (Macaca mulatta).
McDonald A
Neurosci Lett. 2020; 745:135503.
PMID: 33352287
PMC: 7870532.
DOI: 10.1016/j.neulet.2020.135503.
Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A "Dimmer-Switch" Hypothesis.
Ballaz S, Bourin M
Curr Neuropharmacol. 2020; 19(7):925-938.
PMID: 33185164
PMC: 8686311.
DOI: 10.2174/1570159X18666201113145143.
Excitation of Diverse Classes of Cholecystokinin Interneurons in the Basal Amygdala Facilitates Fear Extinction.
Rovira-Esteban L, Gunduz-Cinar O, Bukalo O, Limoges A, Brockway E, Muller K
eNeuro. 2019; 6(6).
PMID: 31636080
PMC: 6838687.
DOI: 10.1523/ENEURO.0220-19.2019.
Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis.
Bortolato M, Bini V, Tambaro S
Pharmaceuticals (Basel). 2016; 3(9):2799-2820.
PMID: 27713377
PMC: 4034098.
DOI: 10.3390/ph3092799.
An Introduction to the Endogenous Cannabinoid System.
Lu H, Mackie K
Biol Psychiatry. 2015; 79(7):516-25.
PMID: 26698193
PMC: 4789136.
DOI: 10.1016/j.biopsych.2015.07.028.
The effect of BLA GABA(A) receptors in anxiolytic-like effect and aversive memory deficit induced by ACPA.
Kangarlu-Haghighi K, Oryan S, Nasehi M, Zarrindast M
EXCLI J. 2015; 14:613-26.
PMID: 26648818
PMC: 4669909.
DOI: 10.17179/excli2015-201.
Septo-hippocampo-septal loop and memory formation.
Khakpai F, Nasehi M, Haeri-Rohani A, Eidi A, Zarrindast M
Basic Clin Neurosci. 2014; 4(1):5-23.
PMID: 25337323
PMC: 4202558.
Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention.
Bowers M, Ressler K
Neuropsychopharmacology. 2014; 40(3):688-700.
PMID: 25176168
PMC: 4289957.
DOI: 10.1038/npp.2014.225.
Neurobiology of schizophrenia onset.
Woo T
Curr Top Behav Neurosci. 2013; 16:267-95.
PMID: 23975845
PMC: 4447495.
DOI: 10.1007/7854_2013_243.
Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia.
Seillier A, Martinez A, Giuffrida A
Neuropsychopharmacology. 2013; 38(9):1816-24.
PMID: 23563893
PMC: 3717536.
DOI: 10.1038/npp.2013.81.
The endocannabinoid system: an overview.
Battista N, Di Tommaso M, Bari M, Maccarrone M
Front Behav Neurosci. 2012; 6:9.
PMID: 22457644
PMC: 3303140.
DOI: 10.3389/fnbeh.2012.00009.
Effects of endocannabinoid system modulation on cognitive and emotional behavior.
Zanettini C, Panlilio L, Alicki M, Goldberg S, Haller J, Yasar S
Front Behav Neurosci. 2011; 5:57.
PMID: 21949506
PMC: 3171696.
DOI: 10.3389/fnbeh.2011.00057.
Gamma oscillation deficits and the onset and early progression of schizophrenia.
Woo T, Spencer K, McCarley R
Harv Rev Psychiatry. 2010; 18(3):173-89.
PMID: 20415633
PMC: 2860612.
DOI: 10.3109/10673221003747609.
Role of cannabis and endocannabinoids in the genesis of schizophrenia.
Fernandez-Espejo E, Viveros M, Nunez L, Ellenbroek B, Rodriguez de Fonseca F
Psychopharmacology (Berl). 2009; 206(4):531-49.
PMID: 19629449
DOI: 10.1007/s00213-009-1612-6.
Endocannabinoids in the retina: from marijuana to neuroprotection.
Yazulla S
Prog Retin Eye Res. 2008; 27(5):501-26.
PMID: 18725316
PMC: 2584875.
DOI: 10.1016/j.preteyeres.2008.07.002.